RHOVAC APS
RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells. Overexpression of RhoC protein is a characteristic of most type of metastatic cancer cells. The cancer vaccine product RV001, already in clinical trial, recognises cells with high concentration of RhoC and stimulate the immune system to target them. RhoVac’s concept focuses on eliminating cancer cells having metastatic potential that escape treatment of the parent tumour via other methods. The company is based in Sweden and Denmark and is publicly traded in Swedish stock market. RhoVac is managed and advised by a senior team of executives with extensive expertise built upon years of experience.
RHOVAC APS
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
2008-01-01
Address:
Hørsholm, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.rhovac.com
Total Employee:
11+
Status:
Active
Contact:
+45 4083 2365
Email Addresses:
[email protected]
Total Funding:
2.5 M EUR
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Horizon 2020
Horizon 2020 investment in Grant - Rhovac ApS
Official Site Inspections
http://www.rhovac.com Semrush global rank: 5.91 M Semrush visits lastest month: 1.4 K
- Host name: splash.curanet.dk
- IP address: 212.237.249.16
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
